Inogen, Inc. (NASDAQ:INGN - Get Free Report) was the target of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 794,700 shares, a growth of 6.7% from the November 15th total of 744,800 shares. Based on an average trading volume of 192,900 shares, the days-to-cover ratio is presently 4.1 days.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of INGN. Price T Rowe Associates Inc. MD lifted its holdings in Inogen by 5.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 23,868 shares of the medical technology company's stock valued at $193,000 after acquiring an additional 1,188 shares during the last quarter. CWM LLC raised its position in Inogen by 2,185.9% in the second quarter. CWM LLC now owns 6,629 shares of the medical technology company's stock valued at $54,000 after purchasing an additional 6,339 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Inogen by 8.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 97,132 shares of the medical technology company's stock valued at $790,000 after purchasing an additional 7,240 shares during the last quarter. Panagora Asset Management Inc. purchased a new position in shares of Inogen during the 2nd quarter worth $256,000. Finally, Monaco Asset Management SAM acquired a new stake in shares of Inogen during the 2nd quarter worth about $610,000. Institutional investors and hedge funds own 89.94% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on INGN shares. StockNews.com upgraded Inogen from a "hold" rating to a "buy" rating in a report on Thursday, December 12th. Needham & Company LLC reiterated a "hold" rating on shares of Inogen in a research report on Friday, November 8th.
View Our Latest Analysis on INGN
Inogen Stock Performance
Shares of INGN stock traded up $0.17 during trading hours on Tuesday, reaching $9.12. The company had a trading volume of 148,559 shares, compared to its average volume of 320,176. Inogen has a 12-month low of $5.08 and a 12-month high of $13.33. The company has a market capitalization of $217.22 million, a price-to-earnings ratio of -3.96 and a beta of 1.02. The stock has a fifty day moving average of $9.50 and a 200-day moving average of $9.73.
About Inogen
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.